{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence. The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST). A response will be determined by at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD","groups":[{"description":"bevacizumab: Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.\n\ndocetaxel: docetaxel IV over 1 hour once a week for 8 weeks\n\nconventional surgery: 8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection\n\nradiation therapy: radiotherapy once daily, 5 days a week, for 8 weeks","id":"OG000","title":"Bevacizumab With Docetaxel and Radiation Therapy"}],"paramType":"NUMBER","populationDescription":"Patients with evaluable tumors at the end of the study","reportingStatus":"POSTED","timeFrame":"5 years","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"participants"}